{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:42:27Z","timestamp":1785760947976,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001273","name":"CHILDREN with CANCER UK","doi-asserted-by":"publisher","award":["N\u00ba2014-178"],"award-info":[{"award-number":["N\u00ba2014-178"]}],"id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","award":["W1075E"],"award-info":[{"award-number":["W1075E"]}],"id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Medulloblastoma (MB) is the most common malignant solid paediatric brain tumour. The standard treatment for MB is surgical resection of the tumour, radiation and chemotherapy. This therapy is associated with high morbidity and adverse side effects. Hence, more targeted and less toxic therapies are vitally needed to improve the quality of life of survivors. NPI-0052 is a novel proteasome inhibitor that irreversibly binds the 20S proteasome subunit. This compound has anti-tumour activity in metastatic solid tumours, glioblastoma and multiple myeloma with a good safety profile. Importantly, NPI-0052 has a lipophilic structure and can penetrate the blood\u2013brain barrier, making it a suitable treatment for brain tumours. In the present study, we performed an in silico gene expression analysis to evaluate the proteasome subunit expression in MB. To evaluate the anticancer activity of NPI-0052, we used a range of MB patient-derived MB cells and cell lines. The synergistic cell death of NPI-0052 with \u03b3-radiation was evaluated in tumour organoids derived from patient-derived MB cells. We show that high expression of proteasome subunits is a poor prognostic factor for MB patients. Also, our preclinical work demonstrated that NPI-0052 can inhibit proteasome activity and activate apoptosis in MB cells. Moreover, we observe that NPI-0052 has a synergistic apoptotic effect with \u03b3-radiation, a component of the current MB therapy. Here, we present compelling preclinical evidence that NPI-0052 can be used as an adjuvant treatment for p53-family-expressing MB tumours.<\/jats:p>","DOI":"10.1038\/s41419-019-2026-y","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T10:35:45Z","timestamp":1571222145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["NPI-0052 and \u03b3-radiation induce a synergistic apoptotic effect in medulloblastoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Eleni","family":"Frisira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swastina Nath","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Badodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine Ayodele","family":"Benjamin-Ombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-405X","authenticated-orcid":false,"given":"David","family":"Michod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-370X","authenticated-orcid":false,"given":"Maria Victoria","family":"Niklison-Chirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis, D. N. et al. The2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97\u2013109 (2007).","journal-title":"Acta Neuropathol."},{"key":"2026_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-015-0547-9","volume":"10","author":"MC Cox","year":"2015","unstructured":"Cox, M. C. et al. Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: a prospective analysis. Radiat. Oncol. 10, 241 (2015).","journal-title":"Radiat. Oncol."},{"key":"2026_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","volume":"27","author":"RM Hill","year":"2015","unstructured":"Hill, R. M. et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27, 72\u201384 (2015).","journal-title":"Cancer Cell"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465\u2013472 (2012).","journal-title":"Acta Neuropathol."},{"key":"2026_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","volume":"18","author":"EC Schwalbe","year":"2017","unstructured":"Schwalbe, E. C. et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 18, 958\u2013971 (2017).","journal-title":"Lancet Oncol."},{"key":"2026_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1101\/gad.302349.117","volume":"31","author":"MV Niklison-Chirou","year":"2017","unstructured":"Niklison-Chirou, M. V. et al. TAp73 is a marker of glutamine addiction in medulloblastoma. Genes Dev. 31, 1738\u20131753 (2017).","journal-title":"Genes Dev."},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.18632\/oncotarget.2431","volume":"5","author":"V Landre","year":"2014","unstructured":"Landre, V., Rotblat, B., Melino, S., Bernassola, F. & Melino, G. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget 5, 7988\u20138013 (2014).","journal-title":"Oncotarget"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2174\/138920310791824057","volume":"11","author":"D Chen","year":"2010","unstructured":"Chen, D. & Dou, Q. P. The ubiquitin\u2013proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 11, 459\u2013470 (2010).","journal-title":"Curr. Protein Pept. Sci."},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1681\/ASN.2006010083","volume":"17","author":"SH Lecker","year":"2006","unstructured":"Lecker, S. H., Goldberg, A. L. & Mitch, W. E. Protein degradation by the ubiquitin\u2013proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 17, 1807\u20131819 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2026_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen, D., Frezza, M., Schmitt, S., Kanwar, J. & Dou, Q. P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11, 239\u2013253 (2011).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","volume":"17","author":"W Fenical","year":"2009","unstructured":"Fenical, W. et al. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 17, 2175\u20132180 (2009).","journal-title":"Bioorg. Med. Chem."},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/nov299","volume":"18","author":"K Di","year":"2016","unstructured":"Di, K. et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood\u2013brain barrier. Neuro Oncol. 18, 840\u2013848 (2016).","journal-title":"Neuro Oncol."},{"key":"2026_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","volume":"115","author":"D Chauhan","year":"2010","unstructured":"Chauhan, D. et al. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115, 834\u2013845 (2010).","journal-title":"Blood"},{"key":"2026_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","volume":"110","author":"CP Miller","year":"2007","unstructured":"Miller, C. P. et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110, 267\u2013277 (2007).","journal-title":"Blood"},{"key":"2026_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-5960-2-10","volume":"2","author":"A Merve","year":"2014","unstructured":"Merve, A. et al. Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion. Acta Neuropathol. Commun. 2, 10 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/sj.onc.1202480","volume":"18","author":"C Blattner","year":"1999","unstructured":"Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J. & Herrlich, P. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18, 1723\u20131732 (1999).","journal-title":"Oncogene"},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-15-2402","volume":"76","author":"CG Hubert","year":"2016","unstructured":"Hubert, C. G. et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 76, 2465\u20132477 (2016).","journal-title":"Cancer Res."},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.yexcr.2012.01.023","volume":"318","author":"N Allocati","year":"2012","unstructured":"Allocati, N., Di Ilio, C. & De Laurenzi, V. p63\/p73 in the control of cell cycle and cell death. Exp. Cell Res. 318, 1285\u20131290 (2012).","journal-title":"Exp. Cell Res."},{"key":"2026_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0014-5793(02)02972-1","volume":"523","author":"C Giovannini","year":"2002","unstructured":"Giovannini, C. et al. Mitochondria hyperpolarization is an early event in oxidized low-density lipoprotein-induced apoptosis in Caco-2 intestinal cells. FEBS Lett. 523, 200\u2013206 (2002).","journal-title":"FEBS Lett."},{"key":"2026_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","volume":"126","author":"K Bensaad","year":"2006","unstructured":"Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107\u2013120 (2006).","journal-title":"Cell"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jbiotec.2016.07.028","volume":"236","author":"DP Ivanov","year":"2016","unstructured":"Ivanov, D. P., Coyle, B., Walker, D. A. & Grabowska, A. M. In vitro models of medulloblastoma: choosing the right tool for the job. J. Biotechnol. 236, 10\u201325 (2016).","journal-title":"J. Biotechnol."},{"key":"2026_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","volume":"7","author":"A Gajjar","year":"2006","unstructured":"Gajjar, A. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 7, 813\u2013820 (2006).","journal-title":"Lancet Oncol."},{"key":"2026_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40478-014-0174-y","volume":"2","author":"N Zhukova","year":"2014","unstructured":"Zhukova, N. et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol. Commun. 2, 174 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"2026_CR24","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","volume":"26","author":"J Bartek","year":"2007","unstructured":"Bartek, J., Bartkova, J. & Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773\u20137779 (2007).","journal-title":"Oncogene"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1754-9485.2012.02349.x","volume":"56","author":"RI Smee","year":"2012","unstructured":"Smee, R. I., Williams, J. R., De-Loyde, K. J., Meagher, N. S. & Cohn, R. Medulloblastoma: progress over time. J. Med. Imaging Radiat. Oncol. 56, 227\u2013234 (2012).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"2026_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0883073808321765","volume":"23","author":"NG Gottardo","year":"2008","unstructured":"Gottardo, N. G. & Gajjar, A. Chemotherapy for malignant brain tumors of childhood. J. Child Neurol. 23, 1149\u20131159 (2008).","journal-title":"J. Child Neurol."},{"key":"2026_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10555-010-9257-9","volume":"29","author":"L Boominathan","year":"2010","unstructured":"Boominathan, L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 29, 613\u2013639 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"2026_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/neuonc\/nos115","volume":"14","author":"A Kunkele","year":"2012","unstructured":"Kunkele, A. et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 14, 859\u2013869 (2012).","journal-title":"Neuro Oncol."},{"key":"2026_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-127","volume":"7","author":"RC Castellino","year":"2007","unstructured":"Castellino, R. C. et al. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 7, 127 (2007).","journal-title":"BMC Cancer"},{"key":"2026_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10735-010-9288-0","volume":"41","author":"M Nekulova","year":"2010","unstructured":"Nekulova, M., Zitterbart, K., Sterba, J. & Veselska, R. Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and Np73 in medulloblastoma cell lines. J. Mol. Histol. 41, 267\u2013275 (2010).","journal-title":"J. Mol. Histol."},{"key":"2026_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1101\/gad.319905","volume":"19","author":"G Asher","year":"2005","unstructured":"Asher, G., Tsvetkov, P., Kahana, C. & Shaul, Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19, 316\u2013321 (2005).","journal-title":"Genes Dev."},{"key":"2026_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrc3711","volume":"14","author":"KT Bieging","year":"2014","unstructured":"Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359\u2013370 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2026_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15\u201316 (1992).","journal-title":"Nature"},{"key":"2026_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.20689","volume":"209","author":"LE Giono","year":"2006","unstructured":"Giono, L. E. & Manfredi, J. J. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J. Cell Physiol. 209, 13\u201320 (2006).","journal-title":"J. Cell Physiol."},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1593\/tlo.09244","volume":"3","author":"E Vlashi","year":"2010","unstructured":"Vlashi, E. et al. Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl. Oncol. 3, 50\u201355 (2010).","journal-title":"Transl. Oncol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2026-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:44:08Z","timestamp":1671212648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2026-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-2026-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"785"}}